Thymosin beta-4 is the most abundant G-actin-sequestering protein in eukaryotic cells, with intracellular concentrations estimated at 200-500 micromolar. It was originally characterized in thymic tissue but is now known to be expressed widely in platelets, neutrophils, cardiac tissue, and most other cell types. Its core biological activity involves maintaining the pool of unpolymerized actin available for rapid cytoskeletal remodeling in response to cellular signals.
Research into TB-500 and the broader thymosin beta-4 system has expanded significantly since studies in the early 2000s demonstrated that Tb4 is secreted from platelets at wound sites and exerts extracellular effects on tissue repair processes. Investigators have since examined angiogenesis, anti-inflammatory signaling, and cardiomyocyte protection in both in vitro and animal model contexts using TB-500 as a pharmacological probe.